Clinical trials: Hepatitis A
Hepatitis E
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.
- Trial name
- NCT05976594
- Testing
- serology and virology detection of hepatitis E virus
- Where
- China
- Volunteers
- 2,900 people
- Sponsor
- Xiamen University
Hepatitis C, Chronic
MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV
This is a 1:1 randomized double-blind Placebo-controlled moncenter Phase IV study to investigate whether a successful interferon-free treatment of HCV-infection with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in combination…
- Trial name
- NCT03003338
- Testing
- OBV/PTV/r and DSV
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Hannover Medical School
Hepatitis C Virus (HCV)
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
Hepatitis C virus (HCV) infection is among the most common of all chronic liver diseases. HCV predominantly affects liver cells and causes the liver to become inflamed and damaged.
- Trial name
- CHOICE (NCT04577482)
- Where
- 10 sites in Russia
- Volunteers
- 42 people
- Sponsor
- AbbVie
AIDS, Hepatitis B
Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients
Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients
- Trial name
- NCT05988879
- Testing
- Peginterferon alfa-2b Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV, Hepatitis C
Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV
The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C.
- Trial name
- CO13Hepavih (NCT03324633)
- Volunteers
- 1,850 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Immune Related Adverse Events, Colitis
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Preliminary data demonstrate that irAEs induced by immune checkpoint blockade can be successfully treated with ECP (Apostolova et al. NEJM 2020).
- Conditions
- Immune Related Adverse Events, Colitis, Hepatitis, Dermatitis
- Trial name
- ECPforIRAE (NCT05414552)
- Testing
- ECP
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- University of Freiburg
Hepatitis C, Chronic
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
This study will evaluate the effect of PF-04136309 in patients with chronic hepatitic C virus infection and abnormal liver enzymes.
- Trial name
- NCT01226797
- Testing
- PF-04136309
- Where
- 10 sites in Hong Kong, India and 3 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Hepatitis C
eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System
Conduct a rigorous formative evaluation of the initial deployment of the Annie texting system across several pilot test sites and from these findings, develop and test an augmented implementation strategy to facilitate more rapid…
- Trial name
- AnnieEval (NCT03898349)
- Testing
- Annie text messaging system, Annie text messaging system with Usual implementation, Annie text messaging system with Augmented implementation
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- VA Office of Research and Development
Hepatitis D
Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy
Spontaneous, pharmacological observational, no-profit, retrospective, multi-center. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers.
- Trial name
- HEP4Di (NCT05962307)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatitis B, Chronic
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
The purpose of the study is to characterize the pharmacokinetic (PK) profile of cetrelimab administered subcutaneous (SC) and optionally intravenous (IV) in chronic hepatitis B (CHB) participants.
- Trial name
- NCT05242445
- Testing
- Cetrelimab
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis
Hepatic Steatosis and Chronic Hepatitis B Virus
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
- Trial name
- NCT05678582
- Testing
- Liver biopsy
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Sohag University
Chronic Hepatitis B, Non-alcoholic Fatty Liver Disease
Chronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention.
In Taiwan, HBV infection is endemic in the adult population. With the westernization of eating habit and lifestyle, metabolic syndrome and related non-alcoholic fatty liver diseases (NAFLD, newly proposed as metabolic dysfunction…
- Trial name
- NCT05956379
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Diphtheria, Tetanus
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT05952596
- Testing
- DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hepatitis C, Drug Use
Future Destinations: Journeys Towards Citizenship
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV), if left untreated it can lead to chronic liver disease, cirrhosis and cancer.
- Trial name
- NCT04159545
- Testing
- Qualitative and quantitative interviews
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Hepatitis C Virus Infection
Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China(STAT)
The present study aims to establish a " one-sample testing platform " and assess the prevalence of hepatitis C in individuals taking routine physical examination or outpatient visit in mainland China.
- Trial name
- STAT (NCT05906459)
- Testing
- Anti-HCV antibody and HCV core antigen testing
- Where
- 3 sites in China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Hepatitis C, Chronic
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve East Asian Subjects with Chronic Hepatitis C…
- Trial name
- NCT02340962
- Testing
- TG-2349, Ribavirin, Interferon Alfa-2a
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Hepatitis B, Chronic
Real-world Study Optimizing Nucleotide-analogues
The goal of this multicenter, observational, prospective study is to observe and compare different anti-viral treatment strategies in a real-world cohort of patients with CHB managed in routine clinical settings in China.
- Trial name
- NCT05937178
- Testing
- ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF
- Where
- 44 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis B Virus
The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).
The investigators' research is aimed at developing more effective, finite approaches for managing individual patients with chronic hepatitis B (CHB).
- Trial name
- BeNEG-DO (NCT02845401)
- Testing
- Stop NA therapy
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- California Pacific Medical Center Research Institute
Hepatitis A Vaccine
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine
The purpose of this study is to evaluate the immunogenicity and safety after one primary dose and one additional dose of inactivated hepatitis A vaccine are administered in Korean healthy children aged 12-23 months.
- Trial name
- VITHA-C (NCT03654664)
- Testing
- Inactivated hepatitis A vaccine, Havrix Inj
- Where
- 10 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Liver Cirrhosis, Hepatitis C, Chronic
Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
Prolonged-Release Pirfenidone (PR-PFD) is an anti-fibrogenic and anti-inflammatory molecule used for the treatment of idiopathic pulmonary fibrosis (approved by FDA) and liver fibrosis (approved in Mexico by COFEPRIS).
- Conditions
- Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder
- Trial name
- NCT05542615
- Testing
- Prolonged-Release Pirfenidone
- Where
- 2 sites in Mexico
- Volunteers
- 60 people
- Sponsor
- University of Guadalajara